Evidence map›Paper›PMID 29349888›Full record

ArticleProtein science : a publication of the Protein Society2018

Distal amyloid β-protein fragments template amyloid assembly.

Thanh D Do, Smriti Sangwan, Natália E C de Almeida, Alexandre I Ilitchev, Maxwell Giammona, Michael R Sawaya, Steven K Buratto, David S Eisenberg, Michael T Bowers

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Thanh D DoDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California.ORCID 0000-0002-1978-4365
Smriti SangwanDepartments of Chemistry and Biochemistry and Biological Chemistry, Howard Hughes Medical Institute, UCLA-DOE Institute for Genomics and Proteomics, University of California, 611 Charles Young Drive East, Los Angeles, California.
Natália E C de AlmeidaDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California.
Alexandre I IlitchevDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California.
Maxwell GiammonaDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California.
Michael R SawayaDepartments of Chemistry and Biochemistry and Biological Chemistry, Howard Hughes Medical Institute, UCLA-DOE Institute for Genomics and Proteomics, University of California, 611 Charles Young Drive East, Los Angeles, California.
Steven K BurattoDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California.
David S EisenbergDepartments of Chemistry and Biochemistry and Biological Chemistry, Howard Hughes Medical Institute, UCLA-DOE Institute for Genomics and Proteomics, University of California, 611 Charles Young Drive East, Los Angeles, California.
Michael T BowersDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California.
University of California, Santa Barbara · USHoward Hughes Medical Institute · US

Funding

Structure and Inhibition of Amyloid in Alzheimer's DiseaseRF1AG054022 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EISENBERG, DAVID · 2016 to 2018
$4.2M
Amyloid Beta-Protein: Wild Type and Familial Mutant Assembly and InhibitionR01AG047116 · NIA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI BOWERS, MICHAEL THOMAS · 2013 to 2016
$1.8M
NIA NIH HHS R01 AG047116NIA NIH HHS RF1 AG054022
6 · The paper itself

Abstract

Amyloid formation is associated with devastating diseases such as Alzheimer's, Parkinson's and Type-2 diabetes. The large amyloid deposits found in patients suffering from these diseases have remained difficult to probe by structural means. Recent NMR models also predict heterotypic interactions from distinct peptide fragments but limited evidence of heterotypic packed sheets is observed in solution. Here we characterize two segments of the protein amyloid β (Aβ) known to form fibrils in Alzheimer's disease patients. We designed two variants of Aβ(19-24) and Aβ(27-32), IFAEDV (I6V) and NKGAIF (N6F) to lower the aggregation propensity of individual peptides while maintaining the similar interactions between the two segments in their native forms. We found that the variants do not form significant amyloid fibrils individually but a 1:1 mixture forms abundant fibrils. Using ion mobility-mass spectrometry (IM-MS), hetero-oligomers up to decamers were found in the mixture while the individual peptides formed primarily dimers and some tetramers consistent with a strong heterotypic interaction between the two segments. We showed by X-ray crystallography that I6V formed a Class 7 zipper with a weakly packed pair of β-sheets and no segregated dry interface, while N6F formed a more stable Class 1 zipper. In a mixture of equimolar N6F:I6V, I6V forms a more stable zipper than in I6V alone while no N6F or hetero-typic zippers are observed. These data are consistent with a mechanism where N6F catalyzes assembly of I6V into a stable zipper and perhaps into stable, pure I6V fibrils that are observed in AFM measurements.

Indexed as

MutationAlzheimer DiseaseAmino Acid SequenceAmyloid beta-PeptidesCrystallography, X-RayHumansMagnetic Resonance SpectroscopyMicroscopy, Atomic ForceModels, MolecularProtein Structure, SecondaryAmyloid beta-Peptidesaggregationamyloidco-assemblyion-mobility mass spectrometryX-ray crystallography

Identifiers

PMID29349888
PMCPMC6032360
OpenAlexW2896526917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.